Celgene bought Juno in a deal valued at about $9 billion.
Seattle biotech company Juno Therapeutics is now officially owned by Celgene, with the completion of a deal that valued Juno at about $9 billion.
Celgene, headquarted in Summit, N.J., agreed to buy Juno in January to combine resources in the cancer research field. Juno specializes in treatments that genetically modify patient’s immune cells so that they can fight off cancer.
Celgene, which already owned about 10 percent of Juno, paid $87 per share for the rest.
Juno’s leading drug candidate, called JCAR017, has shown promising results in treating Non-Hodgkin lymphoma. Celgene said it plans to expand on the research.
Most Read Business Stories
- California: Drugmaker paid doctors to overprescribe Humira
- Amazon considering opening 3,000 cashierless Go stores, report says
- No good deed goes unpunished — Bezos' gift and its discontents | Jon Talton
- China once looked tough on trade, but now its options are dwindling
- Retailer Big 5 sanctioned after Oak Harbor employee suffered racial taunts, death threats
Juno has about 650 employees in its South Lake Union office and a Bothell development plant; both will remain following the acquisition. Juno is hiring for about 100 open positions in the Puget Sound area, according to its website.
Juno spun out of research from the Fred Hutchinson Cancer Research Center and went public in 2014.